Assessing the Effect of the 'Wavy' Application, on Stress and Burden of Disease in Women With INOCA
The Multicentre Wavy Stress Study: Assessing the Effect of the 'Wavy' Application, on Stress and Burden of Disease in Women With INOCA Caused by Vasospasms.
1 other identifier
interventional
117
1 country
6
Brief Summary
For women that experience angina symptoms with underlying vascular spasm as the cause, stress has an aggravating role. Coping with stress is therefore included as an important pillar in dealing with this chronic disease, see the European Association of Percutaneous Cardiovascular Interventions (EACPI) consensus document on INOCA. In practice, stress management focuses on informing and identifying the role stress plays in their lives. A potential stress management tool: "Wavy" aims to help users manage stress more consciously through biofeedback. This research focuses on the effectiveness of stress management applications. The hypothesis is that the app will help to avoid the trigger stress as much as possible and thus reduce the burden of disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2022
Shorter than P25 for not_applicable
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 23, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedFirst Submitted
Initial submission to the registry
November 28, 2023
CompletedFirst Posted
Study publicly available on registry
December 15, 2023
CompletedJanuary 19, 2024
January 1, 2024
5 months
November 28, 2023
January 18, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
seattle angina questionnaire
A valid, reproducible, responsive instrument for assessing disease-specific health status among patients with coronary artery disease
10 weeks
Secondary Outcomes (5)
VAS score on pain
10 weeks
Heart rate variability
10 weeks
Perceived stress score
10 weeks
SF-36
10 weeks
Symptom diary
10 weeks
Study Arms (1)
Control vs intervention
EXPERIMENTALEach subject will take part in a four-week control period, followed by a four-week intervention period.
Interventions
The intervention consists of the application named Wavy. Wavy uses artificial intelligence and the user's feedback to detect stress increasingly more efficient over time. This provides not only real-time feedback on an individual's stress level but also helps the patient to calm down using music guided relaxation. It does so with a music filter, allowing the participant to listen to music where the stress level determines the quality of the music. Thus, relaxing is rewarded by improving the experience. In this process, implicit learning is used to establish a habit of getting better at recognising increased stress levels and getting familiar with reducing stress levels more and more effectively.
Eligibility Criteria
You may qualify if:
- Female.
- Aged 18-70 (upper-limit, because of increased comorbidities and potential difficulties with using the technology).
- Suffering from chronic angina pectoris.
- Diagnosed with INOCA, documented within 2 years, with a coronary angiogram and an abnormal coronary function test (CFT), indicative of either epicardial or microvascular vasospasms.
- Daily usage of a smartphone with an operating system equal to or higher than Android 5.0 (Lollipop) or IOS 10.0.
- Signed written informed consent.
- Excluded criteria:
- She is not available for the assigned research period of approximately 10 weeks from May 2021 till October 2022. The application can be used during the planned holidays.
- She is unable to participate in the stress-reducing exercise, e.g., due to hearing problems.
- A language barrier is present.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Radboud University Medical Centerlead
- VieCuri Medical Centrecollaborator
- The Elisabeth-TweeSteden Hospitalcollaborator
- Maastricht University Medical Centercollaborator
- Maasstad Hospitalcollaborator
- Catharina Ziekenhuis Eindhovencollaborator
- ZonMw: The Netherlands Organisation for Health Research and Developmentcollaborator
- Health Hollandcollaborator
- Netherlands Organisation for Scientific Researchcollaborator
Study Sites (6)
Radboud universty medical center
Nijmegen, Gelderland, 6525GA, Netherlands
Maastricht UMC
Maastricht, Limburg, 6229 HX, Netherlands
VieCuri
Venlo, Limburg, 5900BX, Netherlands
Catharina Hospital
Eindhoven, North Brabant, 5623 EJ, Netherlands
Elisabeth-TweeSteden Hospital
Tilburg, North Brabant, 5042AD, Netherlands
Maasstad Hospital
Rotterdam, South Holland, 3079 DZ, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Suzette Elias-Smale, dr.
Radboud University Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 28, 2023
First Posted
December 15, 2023
Study Start
August 1, 2022
Primary Completion
December 23, 2022
Study Completion
December 31, 2022
Last Updated
January 19, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share